Research Topics
| Nick AndrewsSummaryAffiliation: Health Protection Agency Country: UK Publications
| Collaborators
|
Detail Information
Publications
Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination eraCaroline Trotter
Immunisation Division, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
Vaccine 21:1094-8. 2003..This study provides baseline antibody levels which will facilitate the evaluation of the meningococcal serogroup C conjugate vaccination programme...
Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and WalesNick Andrews
Statistics, Modelling and Economics Department, Health Protection Services, Health Protection Agency, London, United Kingdom
PLoS ONE 6:e28435. 2011..We estimated the effectiveness of PCV-7 against IPD...
Epidemiological designs for vaccine safety assessment: methods and pitfallsNick Andrews
Statistics Modelling and Economics Department, Health Protection Services, Health Protection Agency, 61 Colindale Avenue, London, NW9 5EQ, UK
Biologicals 40:389-92. 2012..The example of MMR and autism, where all three designs have been used, is presented to help consider these issues...- Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and WalesNick J Andrews
Statistics, Modelling and Economics Department, Health Protection Services, Health Protection Agency, London, United Kingdom
Vaccine 30:6802-8. 2012..Based on the VE estimates PPV23 was still considered a cost-effective intervention for the low risk elderly... - A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and DenmarkNick Andrews
Statistics Modelling and Economics Department, Health Protection Services, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom
Vaccine 30:3042-6. 2012..The study therefore shows the potential for vaccine safety collaborations across Europe to detect true associations through use of common protocols and sharing of results or data... - Guillain-Barré syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case seriesNick Andrews
Statistics Modelling and Economics Department, Health Protection Services, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom
Vaccine 29:7878-82. 2011..05 [95% confidence interval (CI) 0.37 to 2.24]). We found no evidence of an increased risk of GBS in the 6 weeks following pandemic influenza vaccination... - Post-licensure safety of the meningococcal group C conjugate vaccineNick Andrews
Statistics Unit, Health Protection Agency, Centre for Infections, London, UK
Hum Vaccin 3:59-63. 2007..15 (0.80-1.67). There was evidence of an increased risk of convulsions and idiopathic thrombocytopenic purpura following MMR vaccination as previously documented... - Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccinesNick J Andrews
Department of Statistics, Modelling and Economics, Health Protection Services, Health Protection Agency, Colindale, London NW9 5EQ, UK
Vaccine 29:7913-9. 2011..Reduction in the interval between doses for earlier protection would be at the cost of reduced immunogenicity. The effect of seasonal vaccine on immunogenicity merits further investigation... - Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United KingdomNick Andrews
Statistics Unit, Health Protection Agency, Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
Vaccine 28:7215-20. 2010..Although there were no other significant differences between vaccines the relative incidence was significantly above one on the day of vaccination for convulsions following DTwP/Hib and for apnoea/collapse following DTaP(5)/Hib/IPV... - Towards elimination: measles susceptibility in Australia and 17 European countriesNick Andrews
Centre for Infections, Health Protection Agency, London, England
Bull World Health Organ 86:197-204. 2008..To evaluate age-specific measles susceptibility in Australia and 17 European countries... - Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccineRay Borrow
Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, P O Box 209, Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom
Clin Vaccine Immunol 17:154-9. 2010.... - Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United KingdomJo Southern
Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom
Clin Vaccine Immunol 16:194-9. 2009..This study demonstrates that NeisVac-C and Menjugate generate good immunogenicity after the first dose at 2 months of age when coadministered with PCV7 and Pediacel and merit further investigation in single-dose priming strategies... - Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of ageElizabeth Miller
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom
Clin Vaccine Immunol 18:367-72. 2011..The United Kingdom infant immunization schedule now recommends that these three vaccines may be offered at one visit at between 12 and 13 months of age... - Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United KingdomDavid Goldblatt
Immunobiology Unit, UCL Institute of Child Health, London, United Kingdom
Pediatr Infect Dis J 29:401-5. 2010..This study was conducted to establish the immunogenicity of licensed PCV (Prevenar) at a reduced, 2 priming dose schedule (2+1) and to evaluate functional responses in the context of vaccine effectiveness... - Reactogenicity of meningococcal C conjugate vaccines when administered at the same time as, or a month prior to or after, tetanus and diphtheria booster vaccinationsJo Southern
Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London, UK
Hum Vaccin 2:237-42. 2006..This single blind study was conducted to address safety concerns regarding coadministration of diphtheria/ tetanus (DT,Td) boosters and meningococcal C conjugate (MCC) vaccines containing diphtheria or tetanus conjugate proteins... - Seroprevalence of influenza A(H1N1)pdm09 virus antibody, England, 2010 and 2011Katja Hoschler
Respiratory Virus Unit, Virus Reference Department, Microbiology Services Colindale, Health Protection Agency, 61 Colindale Ave, London, NW9 5HT, UK
Emerg Infect Dis 18:1894-7. 2012..Population-based seroepidemiology confirms that the third wave of influenza A(H1N1)pdm09 virus circulation was associated with a shift in age groups affected, with the highest rate of infection in young adults... - Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional studyStefan Flasche
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
PLoS Med 8:e1001017. 2011.... - Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United kingdomHelen Findlow
Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, United Kingdom
Pediatr Infect Dis J 31:616-22. 2012..Recent data have demonstrated that 2 of the 3 MCC vaccines showed potential for use as a single priming dose in infancy... - 7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?Yoon Hong Choi
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
PLoS ONE 6:e26190. 2011..However, recent surveillance data show a more rapid replacement of PCV7 IPD cases by non-PCV7 IPD cases than was seen in the US... - Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infJo Southern
Immunisation Department, Centre for Infections, Health Protection Agency, London NW9 5EQ, United Kingdom
Clin Vaccine Immunol 14:1328-33. 2007..15 microg/ml in about 90% of individuals. A booster dose of Hib vaccine given after the first year of life should provide long-lasting protection... - Age-specific incidence of A/H1N1 2009 influenza infection in England from sequential antibody prevalence data using likelihood-based estimationMarc Baguelin
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
PLoS ONE 6:e17074. 2011..The method provides a more accurate and continuous measure of incidence than achieved by comparing prevalence in samples grouped by time period... - Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United KingdomCressida Auckland
Immunisation Department, Centre for Infections, Health Protection Agency, Manchester Royal Infirmary, Manchester, United Kingdom
J Infect Dis 194:1745-52. 2006..Persistence of antibodies may be a more appropriate correlate of long-term protection for MCC vaccines than the ability to generate a booster response on exposure... - Comparison of rubella seroepidemiology in 17 countries: progress towards international disease control targetsAnthony Nardone
Centre for Infections, Health Protection Agency, London, England
Bull World Health Organ 86:118-25. 2008..To standardize serological surveillance to compare rubella susceptibility in Australia and 16 European countries, and measure progress towards international disease-control targets... - The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in EnglandAlbert Jan van Hoek
Immunisation, Hepatitis and Blood Safety Department, Health Protection Services, Colindale, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
J Infect 65:17-24. 2012..Three years of post 7-valent pneumococcal conjugate vaccine (PCV7) data was included to investigate the herd protection effects... - Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological studyElizabeth Miller
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, London, UK
Lancet 375:1100-8. 2010.... - Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunityHelen Campbell
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
Clin Vaccine Immunol 17:840-7. 2010..Modeling suggested that protection against carriage persists for at least 3 years and predicted the stabilization of serogroup C disease at low levels (fewer than 50 cases per year) up to 2015-2016... - Morbidity and mortality of pneumococcal meningitis and serotypes of causative strains prior to introduction of the 7-valent conjugant pneumococcal vaccine in EnglandAlan P Johnson
Department of Healthcare Associated Infection and Antimicrobial Resistance, Health Protection Agency Centre for Infections, London, NW9 5EQ, UK
J Infect 55:394-9. 2007.... - Effectiveness of trivalent and pandemic influenza vaccines in England and Wales 2008-2010: results from a cohort study in general practicePia Hardelid
Statistics Unit, Health Protection Agency Centre for Infections, London, UK
Vaccine 30:1371-8. 2012..The cohort study design could be used each season to estimate VE; however, residual confounding by indication could still present issues, despite adjustment for propensity to consult... - No evidence of an increase of bacterial and viral infections following Measles, Mumps and Rubella vaccineJulia Stowe
Immunisation Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
Vaccine 27:1422-5. 2009.... - Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adultsJo Southern
Immunisation Department, Communicable Disease Surveillance Centre, Health Protection Agency, 61 Colindale Ave, Colindale, London, United Kingdom
Clin Diagn Lab Immunol 11:1100-4. 2004..The study shows that MCC-TT is safe and immunogenic in naive and previously MACP-vaccinated adults, though the magnitude and persistence of postvaccination SBA responses in the latter group were lower... - Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypesAlbert Jan van Hoek
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
PLoS ONE 7:e39150. 2012..We investigated the effect of serotype on clinical presentation, outcome, and quality of life lost from invasive pneumococcal disease (IPD) in the context of the 7, 10, and 13 valent pneumococcal conjugate vaccines (PCV7, PCV10, PCV13)... - No effect of 2008/09 seasonal influenza vaccination on the risk of pandemic H1N1 2009 influenza infection in EnglandRichard Pebody
Health Protection Agency Centre for Infections, 61 Colindale Avenue, UK
Vaccine 29:2613-8. 2011..Vaccine effectiveness did not differ significantly by age-group or hospitalisation status. There was no evidence prior vaccination with TIV significantly altered subsequent risk of pandemic influenza H1N1 2009 infection... - Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in EnglandNick Andrews
Statistics Unit, Hepatitis, and Blood Safety Department, Health Protection Agency Centre for Infections, London, England
J Infect Dis 203:32-9. 2011..The use of a squalene-containing (AS03) pandemic vaccine for high-risk groups in England allowed vaccine effectiveness (VE) of such novel oil-in-water adjuvanted vaccine to be evaluated... - Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research DatabaseJulia Stowe
Immunisation Department, Health Protection Agency Centre for Infections, London, UK
Am J Epidemiol 169:382-8. 2009.... - Mumps complications and effects of mumps vaccination, England and Wales, 2002-2006Chee Fu Yung
Health Protection Agency Centre for Infections, London, UK
Emerg Infect Dis 17:661-7; quiz 766. 2011..14-0.56) when patient had received 1 dose of measles, mumps, and rubella vaccine. The protective effect of vaccination on disease severity is critical in assessing the total effects of current and future mumps control strategies... - Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strainsKatja Hoschler
Health Protection Agency, Specialist and Reference Microbiology Division, ERNVL, Influenza Unit, Centre for Infections, 61 Colindale Avenue, London, UK
Influenza Other Respi Viruses 1:199-206. 2007..Their continuing circulation represents serious pandemic threat, spurring human vaccine development efforts. Initial clinical trials tested vaccines prepared from clade 1 strains circulating in 2004... - Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal associationNick Andrews
Statistics Unit, Health Protection Agency, Communicable Disease Surveillance Centre, London, United Kingdom
Pediatrics 114:584-91. 2004..CONCLUSIONS: With the possible exception of tics, there was no evidence that thimerosal exposure via DTP/DT vaccines causes neurodevelopmental disorders... - Accelerating control of pertussis in England and WalesHelen Campbell
Health Protection Agency, London, UK
Emerg Infect Dis 18:38-47. 2012..e., <3 months of age), teenagers, and adults. Future vaccine program changes may be beneficial, but additional detail is required to inform such decisions... - Development of a focus reduction neutralization test (FRNT) for detection of mumps virus neutralizing antibodiesSunil R Vaidya
Virus Reference Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK
J Virol Methods 163:153-6. 2010..150 microL), and the possibility of automation using 96-well plates. FRNT appears to be a good substitute for PRNT for characterising the immune response to mumps and for vaccine efficacy studies... - Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysisElizabeth Miller
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London NW9 5EQ, UK
BMJ 346:f794. 2013..To evaluate the risk of narcolepsy in children and adolescents in England targeted for vaccination with ASO3 adjuvanted pandemic A/H1N1 2009 vaccine (Pandemrix) from October 2009... - The cost-effectiveness of vaccinating pregnant women against seasonal influenza in England and WalesMark Jit
Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 6BT, United Kingdom
Vaccine 29:115-22. 2010..Key sources of uncertainty are the cost of vaccine delivery and the quality of life detriment due to a clinically apparent episode of confirmed influenza. The cost of vaccine purchase itself is relatively low... - Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesiclesAndrew R Gorringe
Health Protection Agency, Centre for Emergency Preparedness and Response, Porton Down, Salisbury, UK
Clin Vaccine Immunol 16:1113-20. 2009..In conclusion, this N. lactamica OMV vaccine is safe and induces a weak but broad humoral immune response to N. meningitidis... - Bell's palsy and parenteral inactivated influenza vaccineJulia Stowe
Immunisation Department, Health Protection Agency Centre for Infections, London, UK
Hum Vaccin 2:110-2. 2006..78-1.08). There was also no evidence of an increased risk in any age group or following pneumococcal vaccine. A significant increase was seen on the day of vaccination (day 0) probably due to opportunistic recording of cases... - No increased risk of relapse after meningococcal C conjugate vaccine in nephrotic syndromeBrent Taylor
General and Adolescent Paediatric Unit, Institute of Child Health, University College London, London, UK
Arch Dis Child 92:887-9. 2007..To investigate whether meningococcal C conjugate vaccine (MCCV) caused relapse in children with steroid-responsive nephrotic syndrome... - Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in EnglandNick Andrews
Immunisation Division, PHLS Communicable Disease Surveillance Centre, London NW9 5EQ, United Kingdom
Clin Diagn Lab Immunol 10:780-6. 2003.... - Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: a database studyJulia Stowe
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
Vaccine 29:9467-72. 2011..These results neither provide evidence of an increased risk of convulsions following TIV over a 10-year surveillance period nor following a single dose of the ASO3 adjuvanted monovalent H1N1 vaccine in 2009/10... - Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccinationBernard J Cohen
Centre for Infections, Health Protection Agency, London NW9 5EQ, UK
Vaccine 26:59-66. 2007..Measles antibody levels will be measured using the plaque reduction neutralization test (PRNT) to assess antibody responses as a surrogate marker of efficacy... - Rabies antibody levels in bat handlers in the United Kingdom: immune response before and after purified chick embryo cell rabies booster vaccinationJill Morris
Immunisation Department, Centre for Infections, Health Protection Agency, London, UK
Hum Vaccin 3:165-70. 2007..We recommend that the first rabies booster vaccination is given one year after the primary course and subsequent boosters are given every three to five years thereafter... - Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assayJamie Findlow
Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester, M13 9WZ, United Kingdom
Clin Vaccine Immunol 14:1451-7. 2007..These results have implications for the choice of MenB target strains for inclusion in future studies of MenB vaccines and highlight the requirement for standardization of target strains between laboratories... - Cluster-sample surveys and lot quality assurance sampling to evaluate yellow fever immunisation coverage following a national campaign, Bolivia, 2007Lorenzo Pezzoli
European Programme for Intervention Epidemiology Training, European Centre for Disease Control, Stockholm, Sweden
Trop Med Int Health 14:355-61. 2009..To estimate the yellow fever (YF) vaccine coverage for the endemic and non-endemic areas of Bolivia and to determine whether selected districts had acceptable levels of coverage (>70%)... - Immune response to meningococcal serogroup C conjugate vaccine in asplenic individualsPaul Balmer
Manchester Laboratory, Health Protection Agency North West, Manchester Medical Microbiology Partnership, Manchester M13 9WZ, United Kingdom
Infect Immun 72:332-7. 2004..We recommend that, following vaccination of asplenics, either the level of functional antibody should be determined, with a second dose of MCC vaccine offered to nonresponders, or two doses of MCC vaccine should be routinely offered... - Immune response to pneumococcal conjugate vaccination in asplenic individualsElaine Stanford
Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, UK
Hum Vaccin 5:85-91. 2009..Although immunogenic, there is insufficient evidence here to recommend routine PCV7 immunization over PPV23 immunization in adult asplenic individuals... - Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvacJamie Findlow
Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, United Kingdom
Infect Immun 74:4557-65. 2006..These results emphasize the need for standardized methodologies that would allow a more robust comparison of assays between laboratories and promote their further evaluation as correlates of protection against MenB disease... - Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school childrenJamie Findlow
Vaccine Evaluation Department, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, M13 9WZ, UK
Vaccine 23:2623-7. 2005..This was also reflected when > or = 4-fold rises in SBA titres were examined. This finding in sera from toddlers and school children may have implications for PorA based vaccines... - Comparing the immunogenicity of AS03-adjuvanted 2009 pandemic H1N1 vaccine with clinical protection in priority risk groups in EnglandChee Fu Yung
Department of Clinical Epidemiology, Communicable Disease Centre, Tan Tock Seng Hospital, Singapore, Singapore
PLoS ONE 8:e56844. 2013..Current immunogenicity licensing criteria for pandemic influenza vaccine may not correlate with clinical protection in individuals with chronic disease or immunocompromised... - Regression models for censored serological dataGeorge Kafatos
Department of Statistics, Modelling and Economics, Health Protection Agency, London, UK
J Med Microbiol 62:93-100. 2013..Censored regression produced the least biased estimates in comparison with the other methods examined. Moreover, the results suggest using interval-censored regression methods for assay data resulting from dilution series... - Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series studyDominik Zenner
Health Protection Agency, Health Protection Services Colindale, London, UK
Am J Respir Crit Care Med 185:779-84. 2012..The aim of this study was to analyze the epidemiology of TB in pregnancy, and to establish whether pregnancy is an independent risk factor for TB... - Has estimation of numbers of cases of pandemic influenza H1N1 in England in 2009 provided a useful measure of the occurrence of disease?Barry Evans
Health Protection Agency, Centre for Infections, London, UK
Influenza Other Respi Viruses 5:e504-12. 2011..An approach was developed to estimate the number of cases of influenza-like illness (ILI) occurring because of infection with pandemic influenza virus... - Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic surveyJonathan P Clewley
Centre for Infections, Health Protection Agency, London NW9 5EQ
BMJ 338:b1442. 2009.... - Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagersJo Southern
Immunisation Department, Communicable Disease Surveillance Centre, Health Protection Agency, 61 Colindale Avenue, Colindale, London, UK
Vaccine 23:3829-35. 2005.... - Clustered lot quality assurance sampling to assess immunisation coverage: increasing rapidity and maintaining precisionLorenzo Pezzoli
Epidemiology Consultant, London, UK
Trop Med Int Health 15:540-6. 2010.... - Stability of total and rubella-specific IgG in oral fluid samples: the effect of time and temperatureMarianne Morris
Immunisation Division, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London, UK
J Immunol Methods 266:111-6. 2002.... - Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40Wendy A Knowles
Enteric, Respiratory and Neurological Virus Laboratory, Specialist and Reference Microbiology Division, Health Protection Agency, Colindale, London, United Kingdom
J Med Virol 71:115-23. 2003..There is no serological evidence that SV40 entered the human population during the past 80 years, and the possibility of cross-reaction with BKV or JCV antibody must be considered... - Model selection methodology for inter-laboratory standardisation of antibody titresGeorge Kafatos
Statistics Unit, Communicable Disease Surveillance Centre, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
Vaccine 23:5022-7. 2005..If the standardisation equations explained sufficient variability, these were used to convert each country's main serum bank results to a common unitage, thereby allowing international comparisons to be made... - Estimating the number of deaths with rotavirus as a cause in England and walesMark Jit
Modelling and Economics Unit, Immunisation Department, Health Protection Agency, London, UK
Hum Vaccin 3:23-6. 2007..The two methods gave estimates of 3.8 and 3.2 rotavirus deaths a year respectively... - Use of antiviral drugs to reduce household transmission of pandemic (H1N1) 2009, United KingdomRichard G Pebody
Health Protection Agency, London, UK
Emerg Infect Dis 17:990-9. 2011..9% (1/34) when the primary contact was a man (p = 0.010). Of 53 confirmed secondary case-patients, 45 had not received AV prophylaxis. The effectiveness of AV prophylaxis in preventing infection was 92%... - Linking healthcare associated norovirus outbreaks: a molecular epidemiologic method for investigating transmissionBen A Lopman
Department of Infectious Disease Epidemiology, Imperial College London, London, UK
BMC Infect Dis 6:108. 2006..Here, we present a combined molecular and statistical method for assessing:1) whether observed clusters provide evidence of local transmission and2) the probability that anecdotally|linked outbreaks truly shared a transmission event... - Social behavior and meningococcal carriage in British teenagersJenny MacLennan
University of Oxford, Oxford, United Kingdom
Emerg Infect Dis 12:950-7. 2006..Social behavior, rather than age or sex, can explain the higher frequency of meningococcal carriage among teenagers. A ban on smoking in public places may reduce risk for transmission... - Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005Mehmet Ceyhan
Department of Pediatric Infectious Diseases, Faculty of Medicine, Hacettepe University, Ankara, Turkey
Vaccine 25:7233-7. 2007.... - Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infantsEmma Longworth
Meningococcal Reference Unit, Manchester Public Health Laboratory, Withington Hospital, Nell Lane, UK
Vaccine 20:2592-6. 2002..No increase in avidity was observed in the control group. Antibody avidity indices are useful laboratory markers for the priming of immunological memory following vaccination with meningococcal serogroup B OMV vaccines... - Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protectionMoya Burrage
Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, United Kingdom
Infect Immun 70:4946-54. 2002.... - Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdomRay Borrow
Public Health Laboratory Service Meningococcal Reference Unit, Withington Hospital, Manchester, United Kingdom
J Infect Dis 186:1353-7. 2002..6; 95% CI, 338.0-2568.1). This is the first demonstration of immunological memory at 4 years of age in children receiving MCC vaccine on the United Kingdom's 2/3/4-month immunization schedule... - Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdomRay Borrow
PHLS Meningococcal Reference Unit, Withington Hospital, Manchester, United Kingdom
Infect Immun 71:5549-55. 2003..This study provides the first evidence that the number of doses of MCC-TT used in infant immunization schedules could be decreased... - Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household studyDavid Goldblatt
Immunobiology Unit, Institute of Child Health, University College London, UK
J Infect Dis 192:387-93. 2005..pneumoniae or cross-reactive antigens. No longitudinal studies of carriage of and immune responses to S. pneumoniae have been conducted using sophisticated immunological laboratory techniques... - Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlersDavid Goldblatt
Institute of Child Health, University College London, UK
Pediatr Infect Dis J 25:312-9. 2006..The minimum number of doses of pneumococcal conjugate vaccine required for protection is not known. We studied the immunogenicity of a reduced schedule in infants and toddlers... - European seroepidemiology network 2: Standardisation of assays for seroepidemiology of varicella zoster virusFernando de Ory
Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
J Clin Virol 36:111-8. 2006..The aim of the European Sero-Epidemiology Network (ESEN2) is to harmonise the serological surveillance of vaccine-preventable diseases in Europe... - Vaccine effectiveness estimates, 2004-2005 mumps outbreak, EnglandCheryl Cohen
National Institute for Communicable Diseases, Johannesburg, South Africa
Emerg Infect Dis 13:12-7. 2007..5%) in 5- to 6-year-olds to 86% (95% CI 74%-93%) in 11- to 12-year-olds (p<0.001 for 1 or 2 doses). Waning immunity may contribute to mumps outbreaks in older vaccinated populations... - Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in EnglandCaroline Trotter
Department of Social Medicine, University of Bristol, Canynge Hall, Whiteladies Road, Bristol BS8 2PR, United Kingdom
Clin Vaccine Immunol 14:863-8. 2007..With the exception of children aged 3 to 11 months, there was no clear relationship between disease incidence and seroprevalence... - Age-stratified prevalences of pneumococcal-serotype-specific immunoglobulin G in England and their relationship to the serotype-specific incidence of invasive pneumococcal disease prior to the introduction of the pneumococcal 7-valent conjugate vaccinePaul Balmer
Vaccine Evaluation Unit, Health Protection Agency, Manchester Laboratory, Clinical Sciences Building 2, Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom M13 9WZ
Clin Vaccine Immunol 14:1442-50. 2007..These data provide a baseline for natural immunity to the pneumococcal serotypes analyzed prior to the introduction of pneumococcal conjugate vaccine in the United Kingdom... - Idiopathic thrombocytopenic purpura and the second dose of MMRJulia Stowe
Arch Dis Child 93:182-3. 2008 - European Sero-Epidemiology Network 2: standardisation of immunoassay results for pertussis requires homogeneity in the antigenic preparationsAnna Giammanco
Department of Hygiene and Microbiology G D Alessandro, University of Palermo, Palermo, Italy
Vaccine 26:4486-93. 2008.... - Meningococcal C booster not recommended by evidenceH Lucy Thomas
BMJ 337:a1139. 2008 - Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population studyBrent Taylor
Centre for Community Child Health, Royal Free and University College Medical School, University College London Royal Free Campus, London
BMJ 324:393-6. 2002..Conclusions: These findings provide no support for an MMR associated "new variant" form of autism with developmental regression and bowel problems, and further evidence against involvement of MMR vaccine in the initiation of autism... - Development and evaluation of Varicella zoster virus ELISA for oral fluid suitable for epidemiological studiesYamima Talukder
Centre for Infectious Disease, Department of Virology, Barts and the London School of Medicine and Dentistry, 25 29 Ashfield St, London E1 1BB, UK
J Virol Methods 128:162-7. 2005..7% overall, varying slightly with age group. The assay was shown to have good potential for use in large-scale epidemiological studies... - Clinical course of hepatitis C virus during the first decade of infection: cohort studyHelen E Harris
Public Health Laboratory Service Communicable Disease Surveillance Centre, London NW9 5EQ
BMJ 324:450-3. 2002..To determine the clinical course of hepatitis C virus in the first decade of infection in a group of patients who acquired their infections on a known date...